A Study of MEDI-575 in Patients With Advanced Solid Malignancies
Launched by ASTRAZENECA · Apr 12, 2010
Trial Information
Current as of June 24, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Having advanced solid malignancy for which no curative or standard therapies exist
- • Karnofsky performance status of ≥60
- • Patients must have histological confirmed diagnosis of HCC with no standard therapy available (for only expansion part)
- Exclusion Criteria:
- • Inadequate bone marrow reserve or organ function
- • Major surgery within 4 weeks or minor surgery within 2 weeks prior to receipt of MEDI-575. Patients must have no unhealed wounds or unhealed fractures
- • History of allergy or reaction to any component of the MEDI-575 and/or monoclonal antibody
About Astrazeneca
AstraZeneca is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines across various therapeutic areas, including oncology, cardiovascular, respiratory, and autoimmune diseases. With a strong commitment to scientific research and patient-centric solutions, AstraZeneca leverages cutting-edge technology and a robust pipeline to address unmet medical needs. The company collaborates with healthcare professionals, academic institutions, and other organizations to advance clinical trials and deliver transformative therapies, aiming to improve health outcomes and enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nagoya, Aichi, Japan
Matsuyama, Ehime, Japan
Kashiwa, Chiba, Japan
Sunto Gun, , Japan
Chuo Ku, Tokyo, Japan
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials